Abstract
Regarding mammary and splenic neoplasms in dogs, the surgical therapeutic approach is often the method of choice, given its curative potential and the possibility of subsequent histopathological analysis. In veterinary medicine, the incidence of mammary neoplasms is high, especially in unneutered female dogs. Breast carcinoma in situ, with its histological particularities and clinical behavior, requires a careful diagnosis and a precise therapeutic approach, carrying out additional tests such as cytopathology and ultrasound to adequately define the treatment. Surgical excision, associated with the evaluation of adjacent healthy breast tissue, is essential to ensure complete removal of neoplastic tissue, plus it is also indicated to perform ovariohysterectomy (OVH) together with mastectomy. Spleen tumors are similarly common in dogs, especially hemangiosarcoma, which is notable for its aggressiveness and high metastatic rate. Therefore, early diagnosis and precise interventions are essential for a good prognosis, with the affected organ being often removed in its entirety. Therefore, we report the case of a female Shih-Tzu dog, 7 years old and weighing 4kg, who presented, upon palpation, a nodule in the left M3 measuring <1cm with absence of nodular secretion, change in color, itching local or galactorrhea. The patient was referred for regional mastectomy and OVH after cytological examination compatible with carcinoma and, in a pre-operative ultrasound examination, a singular hypoechoic nodular formation, discretely heterogeneous, vascularized on Doppler and in close contact with the splenic capsule was noted in the spleen in its medial parietal portion, measuring 0.96 cm in its longest axis. Thus, during intraoperative visual inspection after OVH and upon approval from the owner, it was decided to perform total splenectomy and, after histopathological examination, it was known that the organ was affected by hemangiosarcoma. The canine was discharged from the hospital a few hours after the end of the surgery, without the subsequent use of adjuvant therapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.